Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature

Leuk Res. 2010 Jul;34(7):e154-6. doi: 10.1016/j.leukres.2010.02.036. Epub 2010 Apr 2.

Authors

Kamal K S Abbi, Syed M Rizvi, Jeffrey Sivik, Subramanian Thyagarajan, Thomas Loughran, Joseph J Drabick

PMID: 20362332
DOI: 10.1016/j.leukres.2010.02.036

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Alemtuzumab
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects*
Antibodies, Neoplasm / pharmacology
Antibodies, Neoplasm / therapeutic use
Antigens, CD / immunology
Antigens, Neoplasm / immunology
Autoimmunity / drug effects
CD52 Antigen
Combined Modality Therapy
Complement Pathway, Classical
Dendritic Cells / drug effects
Glycoproteins / antagonists & inhibitors
Glycoproteins / immunology
Guillain-Barre Syndrome / chemically induced*
Guillain-Barre Syndrome / therapy
Humans
Immunoglobulins, Intravenous / therapeutic use
Leukemia, Prolymphocytic, T-Cell / drug therapy*
Male
Plasmapheresis
Respiration, Artificial
T-Lymphocyte Subsets / drug effects

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antigens, CD
Antigens, Neoplasm
CD52 Antigen
CD52 protein, human
Glycoproteins
Immunoglobulins, Intravenous
Alemtuzumab